Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 2/2012

01.06.2012 | short review

Lung cancer screening: current evidence and recommendations

verfasst von: Michael Mark, MD, Martin Brutsche, MD, PhD, Oliver Gautschi, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Lung cancer is the leading cause of cancer-related death in industrialized countries, especially among current and former smokers. Lung cancer survival is directly correlated to the stage of the disease. Cancer screening can detect cancer at an early stage of the disease. Screening in general should prevent cancer or reduce cancer-specific mortality. Clinical practice guidelines of major medical societies have not recommended routine screening for lung cancer so far. Recent publications of new studies raised interest in lung cancer screening again. In this article, we give an overview on the current evidence of lung cancer screening and discuss our personal recommendations for clinical practice.
Literatur
1.
3.
Zurück zum Zitat Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst. 1996;88:183.PubMed Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst. 1996;88:183.PubMed
4.
Zurück zum Zitat Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two casecontrol studies. BMJ. 2000;321:323–9.CrossRefPubMed Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two casecontrol studies. BMJ. 2000;321:323–9.CrossRefPubMed
5.
Zurück zum Zitat Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136:260–71.CrossRefPubMed Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136:260–71.CrossRefPubMed
6.
Zurück zum Zitat Flieder DB, Port JL, Korst RJ, et al. Tumor size is a determinant of stage distribution in t1 non-small cell lung cancer. Chest. 2005;128:2304.CrossRefPubMed Flieder DB, Port JL, Korst RJ, et al. Tumor size is a determinant of stage distribution in t1 non-small cell lung cancer. Chest. 2005;128:2304.CrossRefPubMed
7.
Zurück zum Zitat Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst. 1980;64:1263.PubMed Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst. 1980;64:1263.PubMed
8.
Zurück zum Zitat Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst. 2000;92(16):1308–16.CrossRefPubMed Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst. 2000;92(16):1308–16.CrossRefPubMed
9.
Zurück zum Zitat Marcus PM, Bergstralh EJ, Zweig MH, Harris A, Offord KP, Fontana RS. Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. J Natl Cancer Inst. 2006;98(11):748–56.CrossRefPubMed Marcus PM, Bergstralh EJ, Zweig MH, Harris A, Offord KP, Fontana RS. Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. J Natl Cancer Inst. 2006;98(11):748–56.CrossRefPubMed
10.
Zurück zum Zitat Humphrey LL, Teutsch S, Johnson M. Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140:740–53.PubMed Humphrey LL, Teutsch S, Johnson M. Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140:740–53.PubMed
11.
Zurück zum Zitat Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355:1763.CrossRefPubMed Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355:1763.CrossRefPubMed
12.
Zurück zum Zitat Henschke C. Clarification of funding of early lung cancer study. N Engl J Med. 2008;358:1862.CrossRefPubMed Henschke C. Clarification of funding of early lung cancer study. N Engl J Med. 2008;358:1862.CrossRefPubMed
13.
Zurück zum Zitat van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer. 2007;120:868.CrossRefPubMed van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer. 2007;120:868.CrossRefPubMed
14.
Zurück zum Zitat van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med. 2009;361:2221.CrossRefPubMed van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med. 2009;361:2221.CrossRefPubMed
15.
Zurück zum Zitat Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.CrossRefPubMed Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.CrossRefPubMed
16.
Zurück zum Zitat Infante M, Lutman FR, Cavuto S, et al. Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial. Lung Cancer. 2008;59(3):355.CrossRefPubMed Infante M, Lutman FR, Cavuto S, et al. Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial. Lung Cancer. 2008;59(3):355.CrossRefPubMed
17.
Zurück zum Zitat Pedersen JH, Ashraf H, Dirksen A, et al. The Danish randomized lung cancer CT screening trial overall design and results of the prevalence round. J Thorac Oncol. 2009;4(5):608.CrossRefPubMed Pedersen JH, Ashraf H, Dirksen A, et al. The Danish randomized lung cancer CT screening trial overall design and results of the prevalence round. J Thorac Oncol. 2009;4(5):608.CrossRefPubMed
18.
19.
Zurück zum Zitat Fletcher RH, Fletcher SW. Prevention. In: Fletcher RH, Fletcher SW, editors. Clinical epidemiology: the essentials. 4th ed. Baltimore: Lippincott; 2005. pp. 147–67. Fletcher RH, Fletcher SW. Prevention. In: Fletcher RH, Fletcher SW, editors. Clinical epidemiology: the essentials. 4th ed. Baltimore: Lippincott; 2005. pp. 147–67.
20.
Zurück zum Zitat Mahesh M, Hevezi JM. Slice wars vs dose wars in multiple-row detector CT. J Am Coll Radiol. 2009;6:2012. Mahesh M, Hevezi JM. Slice wars vs dose wars in multiple-row detector CT. J Am Coll Radiol. 2009;6:2012.
21.
Zurück zum Zitat Wisnivesky JP, Mushlin A, Sicherman N, Henschke CI. Cost-effectiveness of low dose CT screening for lung cancer: preliminary results of baseline screening. Chest. 2003;124:614–21.CrossRefPubMed Wisnivesky JP, Mushlin A, Sicherman N, Henschke CI. Cost-effectiveness of low dose CT screening for lung cancer: preliminary results of baseline screening. Chest. 2003;124:614–21.CrossRefPubMed
22.
Zurück zum Zitat Mc Mahon PM, Kong CY, Bouzon C, et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol. 2011;6:1841–8.CrossRef Mc Mahon PM, Kong CY, Bouzon C, et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol. 2011;6:1841–8.CrossRef
25.
Zurück zum Zitat Crino` L, Weder W, van Meerbeeck J, Felip E. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:103–15.CrossRef Crino` L, Weder W, van Meerbeeck J, Felip E. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:103–15.CrossRef
27.
Zurück zum Zitat Unger M. A pause, progress, and reassessment in lung cancer screening. N Engl J Med. 2006;355:1822–4.CrossRefPubMed Unger M. A pause, progress, and reassessment in lung cancer screening. N Engl J Med. 2006;355:1822–4.CrossRefPubMed
Metadaten
Titel
Lung cancer screening: current evidence and recommendations
verfasst von
Michael Mark, MD
Martin Brutsche, MD, PhD
Oliver Gautschi, MD
Publikationsdatum
01.06.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0006-3

Weitere Artikel der Ausgabe 2/2012

memo - Magazine of European Medical Oncology 2/2012 Zur Ausgabe